The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $13.50

Today's change+0.90 +7.14%
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $13.50

Today's change+0.90 +7.14%
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.

Sarepta Therapeutics Inc up sharply

Sarepta Therapeutics Inc closed up sharply Wednesday, rallying (U.S.)$0.90 or 7.14% to (U.S.)$13.50. Over the last five days, shares have lost 13.41% and are down 33.73% for the last year to date. This security has underperformed the S&P 500 by 41.93% during the last year.

Key company metrics

  • Open(U.S.) $12.66
  • Previous close(U.S.) $12.60
  • High(U.S.) $13.50
  • Low(U.S.) $12.60
  • Bid / Ask(U.S.) $13.19 / (U.S.) $13.48
  • YTD % change-33.73%
  • Volume1,116,415
  • Average volume (10-day)1,196,690
  • Average volume (1-month)1,240,092
  • Average volume (3-month)1,734,176
  • 52-week range(U.S.) $12.58 to (U.S.) $40.00
  • Beta0.74
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEG20.00×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$2.54
Updated December 17 4:00 PM EST. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue1363
Total other revenue--------
Total revenue1363
Gross profit--------
Total cost of revenue--------
Total operating expense35333135
Selling / general / administrative13121010
Research & development22212125
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)----0--
Other operating expenses, total--------
Operating income-34-30-25-33
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-29-34-28-9
Income after tax-29-34-28-9
Income tax, total--000
Net income-29-34-28-9
Total adjustments to net income--------
Net income before extra. items-29-34-28-9
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-29-34-28-9
Inc. avail. to common incl. extra. items-29-34-28-9
Diluted net income-29-34-28-9
Dilution adjustment0000
Diluted weighted average shares41403838
Diluted EPS excluding extraordinary itemsvalue per share-0.71-0.85-0.75-0.23
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.71-0.85-0.75-0.23